Chest:老年糖尿病患者发生社区获得性肺炎具有较高死亡率

2015-11-11 徐媛 MedSci原创

几项研究已经证明,与老年人相比,在非糖尿病年轻患者中发生社区获得性肺炎(CAP)的死亡率更高。本研究旨在比较老年糖尿病(DM)患者发生社区获得性肺炎(CAP)与年轻糖尿病合并CAP患者死亡率以及临床表现。在这项前瞻性研究中收纳了同时患有CAP和DM的患者。利用Fisher正确性检验和Wilcoxon秩和检验分析分类变量、连续变量。通过多因素回归分析评估老年DM合并CAP患者死亡率。研究人员共收纳2

几项研究已经证明,与老年人相比,在非糖尿病年轻患者中发生社区获得性肺炎(CAP)的死亡率更高。本研究旨在比较老年糖尿病(DM)患者发生社区获得性肺炎(CAP)与年轻糖尿病合并CAP患者死亡率以及临床表现。

在这项前瞻性研究中收纳了同时患有CAP和DM的患者。利用Fisher正确性检验和Wilcoxon秩和检验分析分类变量、连续变量。通过多因素回归分析评估老年DM合并CAP患者死亡率。

研究人员共收纳215名患有DM合并CAP患者,其中有157名患者年龄大于65岁。30(19.1%)名老年患者和3(5.2%)名年轻患者死亡(p=0.01)。老年患者较年轻患者合并症种类更多(p= 0.0002),肺炎严重指数(PSI)为IV 、V的重症患者更多(p=<0.0001),第一次合理使用抗生素治疗的时间更晚(p=0.01)。在死亡的30名老年患者中有17名(39.5%)首次合理使用抗生素治疗的时间>8小时,但存活下来的老年患者仅有26名(20.47%)合理使用抗生素治疗的时间>8小时(p= <0.0001)。首次合理使用抗生素治疗的时间≤ 8小时的114名老年患者中仅有13名(11.4%)死亡,然而时间> 8小时的43名老年患者中有17名(39.5%)死亡(p= < 0.0001)。在多变量分析中, DM合并CAP的老年患者院内死亡率提高与首次合理使用抗生素治疗的时间>8小时 (OR 5.9,95% CI 2.0 - 17.4, p= 0.001),PSI为V级的重症CAP(OR 3.4, 95% CI 1.2 - 9.9, p= 0.03),存在合并症(OR 5.4, 95% CI 1.9 - 15.6, p=0.002),未出现症状时间>3天(OR 3.20, 95% CI 1.1 - 9.7, p=0.04)有关。

研究结果表明,当老年糖尿病(DM)患者发生社区获得性肺炎(CAP)时其病死率远高于年轻糖尿病合并社区获得性肺炎患者。临床医生,尤其是在急诊室的医生应尽早开始合理的抗生素治疗,从而改善老年DM患者发生CAP时的高死亡率。

原始出处

mazen bader, MD; yanqing yi, PhD; kassem Abouchehade, PhD; Lisa Bishop, BScPharm; john Hawboldt, BScPharm.Community-Acquired Pneumonia in Older and Younger Adults With Diabetes Mellitus.Chest 2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2042562, encodeId=e5b5204256216, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Oct 17 13:39:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050514, encodeId=f2b2205051462, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 24 17:39:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929224, encodeId=de3a192922415, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Feb 13 01:39:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395630, encodeId=d3011395630fa, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473919, encodeId=1b5a14e3919c0, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479519, encodeId=0c7114e9519a2, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2042562, encodeId=e5b5204256216, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Oct 17 13:39:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050514, encodeId=f2b2205051462, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 24 17:39:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929224, encodeId=de3a192922415, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Feb 13 01:39:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395630, encodeId=d3011395630fa, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473919, encodeId=1b5a14e3919c0, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479519, encodeId=0c7114e9519a2, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2042562, encodeId=e5b5204256216, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Oct 17 13:39:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050514, encodeId=f2b2205051462, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 24 17:39:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929224, encodeId=de3a192922415, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Feb 13 01:39:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395630, encodeId=d3011395630fa, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473919, encodeId=1b5a14e3919c0, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479519, encodeId=0c7114e9519a2, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-02-13 Smile2680
  4. [GetPortalCommentsPageByObjectIdResponse(id=2042562, encodeId=e5b5204256216, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Oct 17 13:39:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050514, encodeId=f2b2205051462, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 24 17:39:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929224, encodeId=de3a192922415, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Feb 13 01:39:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395630, encodeId=d3011395630fa, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473919, encodeId=1b5a14e3919c0, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479519, encodeId=0c7114e9519a2, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2042562, encodeId=e5b5204256216, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Oct 17 13:39:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050514, encodeId=f2b2205051462, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 24 17:39:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929224, encodeId=de3a192922415, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Feb 13 01:39:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395630, encodeId=d3011395630fa, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473919, encodeId=1b5a14e3919c0, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479519, encodeId=0c7114e9519a2, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2042562, encodeId=e5b5204256216, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Oct 17 13:39:00 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050514, encodeId=f2b2205051462, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 24 17:39:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929224, encodeId=de3a192922415, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Feb 13 01:39:00 CST 2016, time=2016-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395630, encodeId=d3011395630fa, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473919, encodeId=1b5a14e3919c0, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479519, encodeId=0c7114e9519a2, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bf97540688, createdName=ms3323097325231039, createdTime=Fri Nov 13 05:39:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]

相关资讯

《社区获得性肺炎诊断和治疗指南》2015年修订要点发布

9月6日,在2015年中华医学会呼吸病学年会上,上海交通大学附属瑞金医院瞿介明教授发布了最新修订的2015年版《社区获得性肺炎(CAP)诊断和治疗指南》(简称“CAP新指南”)并介绍了新指南的特色。本指南由中华医学会呼吸病学分会呼吸感染学组牵头修订,指南的推荐意见均按照国际GRADE标准给予了证据等级和推荐级别。CAP新指南的特点包括:①补充了我国病原学最新资料;②明确提出CAP诊治思路;③CAP

NEJM:PCV13疫苗对老年社区获得性肺炎有明显效果

背景:肺炎球菌多糖结合疫苗可以用于治疗和预防婴幼儿肺炎链球菌性肺炎等疾病,但是对于年龄超过65岁的老人用肺炎球菌多糖结合疫苗来治疗肺炎球菌性肺炎的效果还不得而知。研究方式:我们采用了一个随机、双盲、有安慰剂对照的试验,试验参与人员为84496名年龄大于65岁(包括65岁)患社区获得性肺炎的老人,我们评估13价多糖结合疫苗即PCV13在治疗由疫苗菌株所致的肺炎球菌性肺炎(包括侵入性和非侵入性的肺炎球

JAMA:社区获得性肺炎的经验性治疗有效,一些新证据或属盲从

无论是社区获得性肺炎(CAP)还是医院获得性肺炎,肺炎仍然是发生并发症和死亡的一个重要原因。尽管许多微生物病原体有可能引起肺炎,但最常遇到的是肺炎双球菌和非典型(微)生物(诸如肺炎支原体或军团菌),有时可见金黄色葡萄球菌以及某些革兰阴性杆菌。随着诊断性试验可用性和精密度的增加,在同一例患者中识别出多种病原体的现象越来越常见。 临床医师在选择抗生素疗法时,很少知道病原学的病原体。在门诊条件下,

NEJM:对社区获得性肺炎(CAP)患者使用何种抗生素治疗方案更好(CAP-START研究)?

背景:对于怀疑是社区获得性肺炎(CAP)并且入住普通病房的病人来说,医生依靠经验对病人选择抗生素治疗方案是比较麻烦和复杂的,因为缺乏足够的、可确诊的证据。我们实验的目的在于比较各种不同的经验性治疗方案如β-内酰胺类单一用药治疗、β-内酰胺类与大环内酯类联合治疗、氟喹诺酮类药物单一用药治疗三种方案之间的差异 。结果:一共有656名患者接受β-内酰胺类单一用药治疗;有739名患者接受β-内酰胺类与大环

Ann intern med:糖皮质激素可有效治疗肺炎及并发症、死亡率

来自麦克玛斯特大学的一项研究表,皮质类固醇激素在治疗肺炎方面有着很大的优势,该研究成果在线发表于《内科学年鉴》。该研究第一作者Dr. Reed Siemieniuk说道,“我们的研究可导致一个肺炎治疗方案上的重要改变。糖皮质激素廉价且易获得,数以百万的肺炎患者将因我们的研究发现而受益。”世界上,下呼吸道感染是导致新生儿死亡的第二大常见病因。发达国家因社区获得性肺炎而住院的现象十分常见,而且与急性呼

NEJM:关于社区获得性肺炎的全新统计

社区获得性肺炎是美国成年人住院和死亡之间的主要感染原因。确认放射学和现有的实验室诊断测试对于肺炎发病率估计是迫切需要的。研究人员在芝加哥和纳什维尔进行了以人口为基础的研究,对18岁及以上成年人监测需要入院治疗的社区获得性肺炎。最近住院或严重的免疫抑制患者被排除在外。研究人员对血液,尿液,和呼吸道标本进行了系统的收集培养,血清学检测,抗原检测和分子诊断测试。放射学研究独立检查胸片。研究人员根据年龄和